There has been a spike in severe psychological distress in young Australian adults under 35, according to new analysis from The Australian National University (ANU).

The study—which tracked 3,155 Australians—is the first-of-its-kind to compare mental health data before and during the COVID-19 pandemic.

“Young Australians aged 18 to 24 and those aged 25 to 34 are significantly worse off in terms of mental health than those who are older,” Associate Professor Ben Edwards, from the ANU Centre for Social Research and Methods, said.

For centuries, people have been using mindfulness meditation to try to relieve their pain, but neuroscientists have only recently been able to test if and how this actually works. In the latest of these efforts, researchers at University of California San Diego School of Medicine measured the effects of mindfulness on pain perception and brain activity.

The study, published July 7, 2022 in Pain, showed that mindfulness meditation interrupted the communication between brain areas involved in pain sensation and those that produce the sense of self. In the proposed mechanism, pain signals still move from the body to the brain, but the individual does not feel as much ownership over those pain sensations, so their pain and suffering are reduced.

“One of the central tenets of mindfulness is the principle that you are not your experiences,” said senior author Fadel Zeidan, Ph.D., associate professor of anesthesiology at UC San Diego School of Medicine. “You train yourself to experience thoughts and sensations without attaching your ego or sense of self to them, and we’re now finally seeing how this plays out in the brain during the experience of acute pain.”

Older people with underactive thyroid, which is formally called hypothyroidism, may be at increased risk of developing dementia, according to a new research study published in the July 6, 2022, online issue of Neurology, the medical journal of the American Academy of Neurology. According to the find.

Clinical studies have demonstrated a strong association between Alzheimer’s disease (AD) and delirium. A change to the Tau protein, which can lead to the formation of tangles in brain, is one of the hallmarks of AD pathology, and Tau phosphorylation at threonine 217 (Tau-PT217) and threonine 181 (Tau-PT181) are new plasma biomarkers that can detect early-stage AD. A clinical study led by investigators at Massachusetts General Hospital (MGH) has shown that plasma Tau-PT217 and Tau-PT181 are associated with incidence and severity of postoperative delirium. The findings are published in Annals of Surgery.

Early studies from the same research group at MGH have shown that the ratio of beta amyloid (which causes AD’s signature plaques) to Tau in cerebrospinal fluid is associated with postoperative delirium. Recent studies in other labs have reported that plasma Tau-PT181 concentration distinguishes AD dementia from other neurological disorders. Plasma levels of Tau-PT217 are associated with the changes in cerebrospinal fluid levels of Tau-PT217 and AD development.

In this current study, the team at MGH developed a novel method to measure Tau-PT217 and Tau-PT181 concentrations in plasma of patients, called nanoneedle technology, in collaboration with NanoMosaic (Woburn, MA). “The nanoneedle technology is ultrasensitive, requires a small volume, and can measure low concentrations of molecules, including Tau-PT217 and Tau-PT181,” says lead author Feng Liang, MD, Ph.D., in the Department of Anesthesia, Critical Care and Pain Medicine at MGH. “More than 20,000 nanoneedles are integrated on a silicon substrate assigned to detect one analyte. Each nanoneedle is a single molecule biosensor functionalized with antibodies,” says Liang.